新加白头翁汤治疗活动期溃疡性结肠炎的临床疗效评价  

Clinical efficacy assessment of new Baitouweng decoction in the treatment of active ulcerative colitis

作　　者：缪志伟[1] 王晓瑜[1] 张晓光 张耀辉[1] 徐艳[1] MIAO Zhiwei;WANG Xiaoyu;ZHANG Xiaoguang;ZHANG Yaohui;XU Yan(Department of Gastroenterology,Zhangjiagang TCM Hospital Affiliated to Nanjing University of Chinese Medicine,Zhangjiagang.215600,China)

机构地区：[1]南京中医药大学附属张家港医院脾胃病科,江苏张家港215600

出　　处：《中国中西医结合消化杂志》2021年第2期93-96,共4页Chinese Journal of Integrated Traditional and Western Medicine on Digestion

基　　金：国家自然科学基金青年基金(No:81503536);张家港市科技支撑计划(No:ZKS1730,ZKS1839,ZKS1949)。

摘　　要：目的:观察新加白头翁汤联合西药对比单用西药治疗溃疡性结肠炎(UC)的临床疗效。方法:采用前瞻性队列研究。纳入活动期UC患者50例,对照组24例,试验组26例。试验组予新加白头翁汤联合西药治疗,对照组单用西药治疗,观察临床疗效。结果:与对照组比较,试验组临床缓解率69.2%高于对照组37.5%(P<0.05);临床有效率84.6%高于对照组58.3%(P<0.05),试验组黏膜愈合率为46.2%,对照组29.1%,2组差异无统计学意义。在症状改善方面,试验组对腹痛和黏液脓血便症状改善更好(P<0.05),但在腹泻症状改善方面2组差异无统计学意义(P>0.05)。在理化指标方面,治疗后试验组血沉(ESR)和粪钙卫蛋白(FCP)显著低于对照组(P<0.05,P<0.01),但治疗后2组C反应蛋白(CRP)比较,差异无统计学意义(P>0.05)。治疗过程中2组患者均未发现明显不良反应,安全性较好。结论:新加白头翁汤联合西药治疗UC时可起到明显的增效作用。Objective: To observe the clinical efficacy of new Baitouweng decoction combined with Western medicine in the treatment of ulcerative colitis(UC). Methods: A prospective cohort study was conducted. Fifty patients with active UC, 24 in the control group and 26 in the experimental group were included. The experimental group was treated with new Baitouweng decoction combined with Western medicine, while the control group was treated with Western medicine alone. Results: Compared with the control group, the clinical remission rate of the experimental group was 69.2%, which was higher than 37.5% of the control group(P<0.05);The clinical effective rate of 84.6% was higher than 58.3% of the control group(P<0.05);The mucosal healing rate of the experimental group was 46.2%, which was 29.1% of the control group. In terms of symptom improvement, the experimental group had better improvement on abdominal pain and bloody mucus(P<0.05), but there was no significant difference in the improvement of diarrhea(P>0.05). In terms of physical and chemical indexes, ESR and FCP in the experimental group were significantly lower than those in the control group after treatment(P<0.05, P<0.01), but there was no significant difference in CRP between the two groups after treatment(P>0.05). During the treatment, no obvious adverse reactions were found in the two groups, and the safety was good. Conclusion: New Baitouweng decoction combined with western medicine can play a significant synergistic effect in the treatment of UC.

关 键 词：新加白头翁汤 溃疡性结肠炎 临床疗效 

分 类 号：R574.62[医药卫生—消化系统]